Bank Of New York Mellon Corp Evelo Biosciences, Inc. Transaction History

Bank Of New York Mellon Corp

  • $538 Trillion
  • Q3 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 09, 2023
BUY
$0.17 - $1.57 $2,235 - $20,645
13,150 New
13,150 $2.38 Million
Q4 2022

Feb 14, 2023
BUY
$1.44 - $48.2 $18,936 - $633,830
13,150 New
13,150 $21,000
Q2 2022

Aug 15, 2022
SELL
$1.46 - $3.55 $113,720 - $276,513
-77,891 Reduced 85.56%
13,150 $28,000
Q1 2022

May 11, 2022
SELL
$2.66 - $6.63 $4,420 - $11,019
-1,662 Reduced 1.79%
91,041 $309,000
Q4 2021

Feb 11, 2022
BUY
$6.07 - $12.0 $10,294 - $20,352
1,696 Added 1.86%
92,703 $563,000
Q3 2021

Nov 12, 2021
BUY
$6.79 - $13.9 $104,043 - $212,989
15,323 Added 20.25%
91,007 $640,000
Q2 2021

Aug 11, 2021
BUY
$9.43 - $16.6 $190,787 - $335,851
20,232 Added 36.49%
75,684 $1.04 Million
Q1 2021

May 13, 2021
SELL
$9.71 - $18.6 $29,071 - $55,688
-2,994 Reduced 5.12%
55,452 $593,000
Q4 2020

Feb 09, 2021
BUY
$3.91 - $12.28 $97,241 - $305,403
24,870 Added 74.07%
58,446 $706,000
Q3 2020

Nov 12, 2020
BUY
$3.81 - $5.73 $6,553 - $9,855
1,720 Added 5.4%
33,576 $176,000
Q2 2020

Aug 12, 2020
SELL
$3.53 - $6.12 $33,489 - $58,060
-9,487 Reduced 22.95%
31,856 $156,000
Q3 2019

Nov 07, 2019
SELL
$5.45 - $8.8 $12,295 - $19,852
-2,256 Reduced 5.17%
41,343 $252,000
Q2 2019

Aug 12, 2019
BUY
$6.52 - $9.42 $76,068 - $109,903
11,667 Added 36.54%
43,599 $392,000
Q1 2019

May 14, 2019
SELL
$7.5 - $15.31 $37,132 - $75,799
-4,951 Reduced 13.42%
31,932 $255,000
Q4 2018

Feb 11, 2019
BUY
$7.29 - $13.01 $160,190 - $285,881
21,974 Added 147.39%
36,883 $480,000
Q3 2018

Nov 09, 2018
BUY
$11.93 - $14.76 $11,739 - $14,523
984 Added 7.07%
14,909 $0
Q2 2018

Aug 06, 2018
BUY
$11.39 - $16.26 $158,605 - $226,420
13,925 New
13,925 $165,000

About Evelo Biosciences, Inc.

EVLO Quotes by TradingView
  • Ticker EVLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,994,000
  • Description
  • Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hy...
More about EVLO
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email